Observatoire des droits humains (anglais seulement)

Study: Cost Effective to Test for All Lung Cancer Mutations at Once

(Version anglaise seulement)

Testing advanced lung cancer patients for all of the possible genetic mutations that could be driving their cancer at once is more cost effective than testing for one or a limited number of genes at a time, U.S. researchers reported Wednesday. There are eight targeted therapies doctors can use to treat nonsmall-cell lung cancer (NSCLC) patients based on genetic defects, and more treatments are in clinical trials or awaiting approval. Companies such as Foundation Medicine Inc. and...

Lire l'article complet